USNA

USANA Health Sciences Inc. - 10-Q Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended October 2, 1999, and the nine months ended on that date. USANA Health Sciences Inc. develops and manufactures nutritional, personal care, and weight management products distributed via a network marketing system. As of the period end, the company operated in the United States, Canada, Australia, New Zealand, the United Kingdom, and had recently initiated operations in the Netherlands and Hong Kong.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Decline: The company reported a net loss of $0.8 million for the quarter, compared to a net earnings of $2.5 million in the prior year quarter. For the nine-month period, net earnings dropped 47.3% to $3.6 million from $6.9 million.
• Restructuring and Impairment: A significant non-recurring charge of $4.4 million was recorded in the third quarter. This included $2.7 million for restructuring (primarily UK operations) and $1.7 million for asset impairment related to a new computer system implementation.
• Revenue Growth: Net sales increased 0.7% quarter-over-quarter and 7.8% for the nine-month period, driven by a 15.8% increase in the total customer base (distributors and preferred customers).
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 25.4% for the quarter and 26.7% for the nine months, attributed to international expansion costs, infrastructure building, and convention expenses.
• Liquidity Shift: Net working capital turned negative ($2.4 million deficit) from a positive $7.9 million at the start of the year, largely due to a $23.5 million stock repurchase and related party advances.

Guidance, Outlook, and Risks

Management Commentary: Management expects the restructuring initiative to lower relative operating costs by approximately $3.5 million annually. The company is transitioning to a new Oracle-based custom network marketing system and plans to launch an e-commerce website in mid-2000. The CEO, Dr. Myron W. Wentz, does not receive a salary.

Capital Structure: The company secured $25 million in new credit facilities (a $10 million term loan and $15 million revolving line) to finance a $20.9 million stock repurchase from the founder's holding company. The company expects to retire this debt by the end of fiscal 2001.

Risks and Contingencies:

• Year 2000 Compliance: The company is implementing a new ERP system to ensure Year 2000 compliance, with installation expected in Q1 2000. While no material issues are currently anticipated, risks remain regarding third-party suppliers.
• Market Risk: International sales represented 46.4% of net sales for the nine months ended October 2, 1999, exposing the company to foreign currency exchange fluctuations.
• Dependence on Network Marketing: Revenue is heavily dependent on the efforts of independent distributors and the stability of the network marketing model.

Investor Verification Checklist

• Debt Covenants: Verify continued compliance with the restrictive covenants of the new $25 million Bank of America credit facility.
• Restructuring Execution: Monitor the actual realization of the projected $3.5 million annual cost savings from the UK restructuring and asset liquidation.
• Stock Repurchase Impact: Assess the long-term benefit of the $23.5 million equity reduction against the current negative working capital position.
• International Growth: Confirm the sustainability of sales growth in the UK and Australia/New Zealand markets, which drove the recent customer base expansion.
• Year 2000 Readiness: Validate the successful deployment of the new ERP and distribution systems by the end of fiscal 1999 to mitigate operational risks.